Business Context and Reporting Period
This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) on May 13, 2010. The filing addresses two primary matters: the announcement of financial results for the first quarter ended March 31, 2010, and a material restatement of the consolidated financial statements for the years ended December 31, 2007, 2008, and 2009.
Key Financial Metrics and Restatement Details
The filing details a restatement of net loss per share due to an error in calculating the impact of accrued dividends on 6% Convertible Exchangeable Preferred Stock. The restatement does not affect net cash flows, total net loss, or the consolidated balance sheet.
| Year Ended Dec 31 | 2007 | 2008 | 2009 |
|---|---|---|---|
| Net Loss Reported (Original) | $(24,053,000) | $(40,386,000) | $(19,570,000) |
| Preferred Dividends Adjustment | $(307,000) | $(1,227,000) | $(1,228,000) |
| Net Loss Applicable to Common Shareholders | $(24,360,000) | $(41,613,000) | $(20,798,000) |
| Loss Per Share (Basic & Diluted) - Revised | $(1.23) | $(2.04) | $(0.94) |
| Loss Per Share (Basic & Diluted) - Original | $(1.21) | $(1.98) | $(0.88) |
Additionally, the filing notes errors in the presentation of cash flow disclosures regarding Preferred Stock dividends for 2007-2009, specifically the classification of certain payments between operating and financing activities. These errors had no effect on net cash flows.
Material Changes Versus Prior Period
The primary material change is the revision of historical earnings per share (EPS) figures. The net loss per share for 2009 was revised from $(0.88) to $(0.94). Similar downward revisions occurred for 2007 and 2008. The filing explicitly states that the restatement has no effect on the reported net loss or the consolidated balance sheet.
Guidance, Outlook, and Risks
Management Commentary: The Company's board of directors determined that the previously reported financial results for 2009 and the related audit report should no longer be relied upon. Management reported the error to the audit committee on May 10, 2010, and the board approved the restatement on May 13, 2010.
Outlook and Timing: The Company expects to file an amendment to its Form 10-K (the "Amendment") reflecting the restated financial statements within the next several days. A conference call to review Q1 2010 results was scheduled for May 13, 2010.
Risks and Contingencies: The error stemmed from the failure to include accrued unpaid dividends on Preferred Stock in the EPS calculation, despite the dividends being accrued in the financial statements. The Company had resolved not to declare cash dividends on the Preferred Stock starting April 6, 2009, to reduce expenditures.
Important Facts for Investor Verification
- Verify the upcoming filing of the Form 10-K/A amendment to confirm the restated financial statements.
- Review the Q1 2010 press release (Exhibit 99.1) for current operational performance, as this 8-K focuses on historical restatements.
- Confirm the status of the 6% Convertible Exchangeable Preferred Stock and the impact of accrued but unpaid dividends on future liquidity.
- Note that the restatement affects EPS calculations for 2007, 2008, and 2009 but does not alter total net loss or cash flow figures.